Physician profile
Muhammad H Bashir
NPI 1114230430
$1,942.66
in general payments reported to CMS, 2019-2025
21 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $176 · 2021: $274 · 2022: $377 · 2023: $433 · 2024: $341 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $865 · Education: $99.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $864.69 |
| Education | $99.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $425.70 | 2020-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $305.73 | 2019-2024 | Velphoro |
| Novartis Pharmaceuticals Corporation | $229.10 | 2022-2025 | |
| Akebia Therapeutics INC | $178.31 | 2021-2024 | Vafseo |
| Amgen INC. | $121.85 | 2019-2024 | Tavneos, Krystexxa |
| Mallinckrodt Hospital Products INC. | $108.57 | 2022-2025 | Terlivaz |
| Travere Therapeutics, INC. | $102.45 | 2021-2025 | Filspari |
| Vifor Pharma, INC. | $93.10 | 2019-2023 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $78.72 | 2019-2021 | |
| Opko Pharmaceuticals, LLC | $59.73 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.25 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $37.22 | 2023-2024 | Farxiga |
| Shire North American Group INC | $32.91 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.88 | 2023 | |
| Alexion Pharmaceuticals, INC. | $17.62 | 2023 | Ultomiris |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $17.46 | 2020 | |
| Glaxosmithkline, LLC. | $17.45 | 2023 | Benlysta |
| Lilly USA, LLC | $16.73 | 2024 | Jardiance |
| Daiichi Sankyo INC. | $16.29 | 2024 | Injectafer |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
| Athena Bioscience, LLC | $12.99 | 2023 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Bashir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.